DaVita Inc. Earnings Recaps
Q2 2026
Aug 6, 2026
Shares dropped 19.3% following DaVita’s Q2 report as investors reacted negatively to margin compression and a cautious outlook driven by lower sequential revenue per treatment and expected headwinds from declining ACA enrollment and phosphate binder reimbursement.
Key takeaways
- Volume growth accelerated year-over-year, slightly surpassing expectations due to improvements in patient mortality.
- Revenue per treatment declined sequentially, negatively impacted by a lower commercial mix from ACA enrollment declines and reduced contribution from phosphate binders.
- Gross margin pressure emerged, partly reflecting the transition of phosphate binders into the Medicare dialysis bundle and reimbursement complexities.
- Management highlighted support for upcoming CMS ESRD payment rule changes but acknowledged proposed Medicare base rate updates will likely trail industry cost inflation.
- New dialysis therapies (expanded HD with medium cutoff dialyzers) were positioned as a future growth and clinical advancement opportunity but have yet to offset current financial headwinds.
Q1 2026
May 7, 2026
DaVita's stock surged 25.8% as the company delivered better-than-expected volume growth, raised full-year guidance, and demonstrated early traction from technology investments supporting operational efficiency and clinical outcomes.
Key takeaways
- Treatment volume came in slightly ahead of forecast, driven by better-than-expected mortality trends and patient transfers from Fresenius clinic closures.
- Raised full-year volume growth expectations to 25-50 basis points, attributing about half the gain to Fresenius transfers and half to organic improvement.
- Adjusted operating income of $482 million beat internal forecasts by approximately $50 million, with half due to actual performance and half due to timing benefits.
- Adjusted EPS guidance was increased to a $14.10–$15.20 range, reflecting higher volume and lower patient care costs.
- Continued investments in data infrastructure and AI, including deployment of ScheduleHub to optimize scheduling, are positioning the company for operational scale and improved clinical outcomes.
Q3 2025
Oct 30, 2025
DaVita reported a strong third quarter in 2025, achieving adjusted operating income of $517 million and adjusted earnings per share of $2.51, maintaining its trajectory for the full year.
Key takeaways
- Adjusted operating income and earnings per share were consistent with internal expectations, reaffirming guidance for the year.
- The company's clinical research division, DaVita Clinical Research, remains a leader in advancing kidney care, conducting over 500 clinical trials and contributing to FDA approvals.
- Effective management of patient care costs, despite a 1.5% year-over-year decline in U.S. treatment volume, has supported financial stability.
- Strategic investments in technology infrastructure and AI solutions are expected to enhance patient care and operational efficiency long-term.
- Full-year adjusted operating income guidance narrowed to $2.035 – $2.135 billion, with earnings per share projected between $10.35 and $11.15.